Pacira's Exparel For Nerve Block Use Gets Day-Plus US FDA Panel Review
Executive Summary
Pacira believes new clinical trial of post-surgical pain medication will satisfy FDA concerns raised in complete response letter for its supplemental NDA.
Topics
- Subjects
- Advisory Committees
- Regulation
- FDA
- Therapy Areas
- Aesthetics
- Industries
- BioPharmaceutical
- Regions
- North America
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PS122283
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
PS122283
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.